Podcasts

In this CAPcast interview, Dr. Richard Scanlan discusses his experiences bringing COVID-19 testing online at his institution, including some lessons learned. Dr. Scanlan is the medical director of the Oregon Health and Sciences University Hospital laboratory in Portland.

In this CAPcast, Dr. Baird discusses lessons learned from testing and personnel challenges when ramping up testing capacity.

UDS results can impact decisions related to a patient’s treatment, including discontinuation of opioid therapy or removal of the patient from the treatment program, explains Barbarajean Magnani, MD, PhD, FCAP, in this CAPcast interview.

Drug testing is critical to patient care, whether it’s for compliance with prescribed medications, identification of drugs in the immediate overdose setting, or exposure to toxins that may cause long-term deleterious effects, such as lead.

In this CAPcast interview, Dr. Michael Mina, Associate Medical Director of Clinical Microbiology and Molecular Virology at Brigham and Women’s Hospital’s Department of Pathology in Boston, discusses the current outlook of the virus and what pathologists need to know about their role in diagnosis and treating patients suspected to have contracted this virus.

The advent of new molecularly targeted treatment strategies for patients with advanced colorectal cancer places anatomic and molecular pathologists as key players in the delivery of care for this large patient population. Specifically, advanced colorectal cancer encompasses patients presenting with Stage IV cancer, or those who experience a cancer recurrence, explains Dr. Joseph Willis in a new CAP.org article, 'Testing of Specimens From Patients With Advanced Colorectal Carcinoma.'

In this CAPcast, Dr. David Gang and Dr. Matthew Foster-two leaders with the CAP’s Federal and State Affairs Committee--discuss their recent trips to Capitol Hill to meet with their legislators on surprise billing.

In this CAPcast interview, Dr. Larsen discusses what CAP members need to know about the pathology of vaping-associated lung injury.

Recently the CAP observed that CMS is citing blood gas labs for not having appropriate personnel during their validation inspections, as Dr. Earle Collum outlines in this CAPcast interview.